Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to ...

Genethon is determined to bring GNT0004 to market for young patients and their families who are waiting for a therapeutic ...

A mouse model study of Precision BioSciences’ gene-editing therapy PBGENE-DMD found it produced long-term functional ...

Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.

Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver ...

European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...

BASEL, Switzerland I July 25, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

EMA's CHMP issued an opinion not to recommend Elevidys (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) Roche will continue its dialogu ...

The Food and Drug Administration has paused distribution of the gene therapy Elevidys following the death of a third patient ...

CHMP issues negative opinion on conditional marketing authorization for Roche’s gene therapy, Elevidys for Duchenne muscular dystrophy: Basel Monday, July 28, 2025, 15:00 Hrs [I ...